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Objectives: To report incidence, indication, and timing of reinterventions after thoracic endovascular aortic repair
(TEVAR) and identify subgroups most prone to reinterventions.
Methods: Between January 1997 and March 2010, a total of 264 patients received TEVAR in our institution. During
follow-up, 58 patients (39 men, median age 63 years, range 28-87 years) required a total of 68 reinterventions, which
represent the study population of this retrospective, single center analysis. The mean follow-up of all 264 patients was
31.2 months (range 0-141 months).
Results: The overall reintervention rate was 22%: 1-, 3-, and 5-year free reintervention rates were 82%  3%, 74%  3%,
and 70%  4%, respectively. Indications for reintervention were predominately endoleaks (41%) and progression of the
underlying aortic disease (29%). Reinterventions were performed by endovascular means in 44%, by open repair in 35%
(including 11 conversions), and by hybrid procedures in 21%. Multiple logistic regression analysis revealed patients with
chronic expanding aortic dissections (odds ratio [OR]: 2.35), hybrid aortic procedures (OR: 2.11), and connective tissue
diseases (OR: 7.54) at an increased risk for reintervention. The necessity for reintervention did not influence survival in
this cohort (log-rank test P  .1706).
Conclusions:TEVAR is associated with a relevant reintervention rate, predominately caused by endoleaks and progression
of the aortic pathology. Patients with chronic expanding aortic dissections, hybrid aortic procedures, and connective





























aOver the last decade, thoracic endovascular aortic
repair (TEVAR) has evolved as the first-line treatment
option for many thoracic aortic pathologies due to re-
duced perioperative morbidity and mortality rates in
selected patients.1-3 The main drawback of TEVAR con-
sists of procedure-associated complications, especially
endoleak formation, migration, material fatigue, or stent
graft collapse that endanger early-, mid- and long-term
treatment success and cause further open/endovascular
reinterventions. Additionally, a significant proportion (12%-
60%) of patients, especially with aortic dissections, experience
disease progression during follow-up after TEVAR, and thus
requires further surgical procedures.4-6
The aim of this study was, therefore, to analyze inci-
dence, indication, and timing of required reinterventions
after TEVAR and to identify potential predictors for pa-
tients most prone to reinterventions.
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Patient population. The study design represents a
etrospective single-center analysis. Between January 1997
ndMarch 2010, a total of 264 patients received TEVAR in
ur institution. During a mean follow-up of 31.2 months
range, 0-141 months), a total of 58 (21.9%) patients (39
en, median age 63 years; range, 28-87 years) required 68
einterventions. Indications for treatment are shown in
able I and show a significantly higher reintervention rate
P .013) in patients treated for chronic expanding aortic
issections (CEAD). Baseline characteristics in these pa-
ients are shown in Table II and revealed a significantly
igher proportion of patients with connective tissue disease
CTD) in the reintervention group (P  .003).
Procedure. All surgical procedures were performed in
n operating room equipped with fluoroscopic and angio-
raphic capabilities (Series 9800; OEC Medical Systems,
nc, Salt Lake City, Utah until April 2007, after that Axiom
; Siemens, Forchheim, Germany) and a carbon fiber
perating table. The following stent grafts have been used:
alent/Valiant/Captivia (Medtronic Vascular, Santa Rosa,
alif), TAG/C-TAG (W. L. Gore and Associates, Flagstaff,
riz), Zenith (Cook Inc, Bloomington, Ind), and Endofit
LeMaitre Vascular, Burlington, Mass). The procedure
rotocol has been published before.7 Procedure-related
ata are presented in Table III and showed no influence of
he type of stent graft used, or the time period of initial
reatment regarding reintervention. There was a significant
igher rate of reinterventions in elective cases (P  .015)
nd for patients needing aortic (arch and/or visceral) hy-
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ized tomographic angiography (CTA) before discharge,
clinical examination, plain chest radiography and CTA/
magnetic resonance angiography (MRA) 6 and 12 months
postoperatively and annually thereafter.
Definitions and statistical analysis. Reintervention
was defined as any TEVAR and/or aortic disease related
Table I. Indication of all thoracic endovascular aortic repa




Acute aortic dissection 32 (12%)
Traumatic transection 17 (6%)
ABF 12 (5%)
IMH 9 (3%)
Patch rupture/aneurysm 6 (2%)
ABF, Aortobronchial fistula; CEAD, chronic expanding aortic dissection; IM
Table II. Baseline characteristics of all thoracic endovascu
Parameter Total (n  264)
Gender (male) 188 (71%)
Age 63 (21-89)
Hypertension 230 (87%)
History of smoking 126 (48%)
Diabetes 32 (12%)




Previous aortic surgery 60 (23%)
CHD, Coronary heart disease; COPD, chronic obstructive pulmonary disea
Values are presented as median (range) or n (%).
Table III. Procedure-related data of all thoracic endovasc
Parameter Total (n  264)
Fr
Stent grafts
- TAG 158 (60%)
- Talent 44 (17%)
- Valiant 34 (13%)
- Zenith 18 (7%)
- C-TAG 3 (1%)
- Captivia 1 (0.3%)
- Other 8 (3%)
Treatment period
- 1997-2001 51 (19%)
- 2002-2006 115 (43%)
- 2007-2010 98 (37%)
Procedure
- Elective 126 (48%)
- Emergency 138 (52%)
Hybrid procedures 75 (28%)additional open, endovascular or hybrid procedure during oollow-up, including early and late conversion. Endoleaks
ere categorized as previously described by White et al.8
ybrid procedures were defined as aortic arch vessel
nd/or visceral vessel debranching combined with TEVAR
o exclude the aortic pathology. Our experience with aortic
ybrid repair has been reported before.9,10 Disease pro-
ression was defined based on the underlying aortic pathol-




(n  58) P value
101 (78%) 28 (22%) .881
43 (88%) 6 (12%) .120
21 (62%) 13 (38%) .013
27 (84%) 5 (16%) .495
15 (88%) 2 (12%) .539
9 (75%) 3 (25%) .721
5 (56%) 4 (44%) .098
5 (83%) 1 (17) .998
tramural hematoma; PAU, penetrating aortic ulcer.




(n  58) P value
49 (71%) 39 (70%) .995
63 (21-89) 63 (28-87) .984
80 (86%) 50 (89%) .377
02 (49%) 24 (43%) .453
23 (11%) 9 (16%) .357
52 (25%) 13 (23%) .862
40 (19%) 15 (27%) .265
77 (37%) 21 (36%) .999
3 (1.4%) 6 (11%) .0035
46 (22%) 14 (25%) .719
D, connective tissue disease.




(n  58) P value
1 (77%) 37 (23%) .446
4 (77%) 10 (23%) .840
7 (79%) 7 (21%) .998
6 (88%) 2 (12%) .378
3 (100%) 0 (0%) NA
1 (100%) 0 (0%) NA
6 (71%) 2 (29%) NA
7 (73%) 15 (27%) .134
5 (82%) 20 (18%) .334
6 (77%) 22 (23%) .999
0 (72%) 36 (28%) .015
7 (84%) 21 (16%) .015
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June 20111530 Geisbüsch et alment of an aortic aneurysm/penetrating aortic ulcer (PAU)
in the thoracic aorta. Progression of disease in acute type B
dissections/intramural hematoma (IMH) was defined as
new onset of pathology-related complications (eg, rapid
expansion/rupture/end organ ischemia) after TEVAR. In
chronic aortic type B dissections, continuous aortic expan-
sion in the dissected aortic segment was defined as disease
progression. In aortobronchial fistula (ABF), recurrence of
typical clinical symptoms was defined as disease progres-
sion. Data are expressed as mean  SD or median (range).
Survival and reintervention-free survival estimates were
generated using the Kaplan-Meier analysis. Log-rank test
was used for survival comparisons. Fisher exact test and
Mann-Whitney U test were used for categorical, respectively
continuous variables. Multiple logistic regression analysis was
used to identify risk factors affecting reintervention. All statis-
tical analysis was performed using MedCalc (Version 9.5.2;
MedCalc Software, Mariakerke, Belgium).
RESULTS
Overall reintervention rate was 22% (58/264), with a
total of 68 reinterventions performed in 58 patients. Six
patients required two reinterventions and one patient
(Marfan syndrome) required five reinterventions. Indica-
tion for reinterventions (Table IV) consisted predomi-
nantly of endoleaks (41%) and progression of the aortic
disease (29%). Additional causes included stent graft col-
lapse (two patients with acute aortic transections) and stent
graft compression at the overlapping zone of two en-
dografts caused by a rigid dissection membrane in a patient
with a CEAD.11 One patient received a subclavian transpo-
sition after paraplegia in sequel of a thoracoabdominal
hybrid procedure and primary overstenting of the left sub-
clavian artery (LSA). One patient with a recurrent episode





- Type I 21
- Type II 4
- Type III 2
Disease progression 20 (29
Bypass occlusion/stenosis (hybrid cases) 6 (9%
Arm claudication/subclavian steal 4 (6%
Retrograde type A dissection 2 (3%
Stent graft collapse 2 (3%
Stent graft compression 1 (1.5
Paraplegia 1 (1.5
AEF 2 (3%
Aortobronchial fistula 1 (1.5
Material fatigue (wire fracture) with
ABF
1 (1.5
Stent graft infection 1 (1.5
ABF, Aortobronchial fistula;AEF, aortoesophageal fistula; EVR, endovascul
transluminal angioplasty.of hemoptysis 5 years after TEVAR for a thoracic aortic 7neurysm received distal and proximal stent graft extension
o cover successfully a suspected ABF.
Conversion was necessary in 11 patients (4.1%). This
ncludes three patients with a disease progression at the
scending aorta/aortic arch, two patients with retrograde
issection after TEVAR (initially treated for a CEAD/
MH), and two patients with an aortoesophageal fistula
hich received planned conversion after bridging TEVAR.
dditionally, one patient showed a longitudinal wire frac-
ure with aortic wall perforation and consecutive ABF and
eceived successful conversion. One patient experienced
tent graft infection after repeated trauma surgery and
nderwent successful conversion. Emergency conversion
as necessary in two further patients (one intraoperative
tent graft collapse; one aortic rupture due to a type I
ndoleak two years after TEVAR).
Reinterventions were performed by endovascular
eans in 44% (30/68), by open repair in 35% (24/68,
ncluding 11 conversions), and by aortic hybrid procedures
n 21% (14/68). Parameters showing a significant higher
eintervention rate in univariate analysis (CTD, CEAD, and
ortic arch hybrid procedures) were entered in a multiple
ogistic regression model (Table V), which proved those
arameters as risk factors for reinterventions. The 1-, 3-,
nd 5-year reintervention free survival was 82%  3%,








4 (20%) 13 (65%) 3 (15%)
5 (83%) 1 (17%) NA
Subclavian transposition
Conversion
Conversion (n  1)







ir;HAR, hybrid aortic repair;OR, open surgical repair; PTA, percutaneous
able V. Risk factor analysis regarding reintervention
ariable Odds ratio 95% CI P value
EAD 2.35 1.05-5.28 .037
ybrid procedures 2.11 1.11-4.01 .023
TD 7.54 1.72-32.99 .007
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Volume 53, Number 6 Geisbüsch et al 1531necessity for reintervention did not influence survival (Fig
2) in this cohort (log-rank test P  .1706).
DISCUSSION
The present series shows that TEVAR is associated with
a relevant reintervention rate (22%), predominately caused
by endoleaks and progression of the aortic pathology. The
analysis further revealed patients with chronic expanding
aortic dissections (odds ratio [OR], 2.35), hybrid aortic
procedures (OR, 2.11), and connective tissue diseases (OR,
7.54) at an increased risk for reintervention.
Reintervention rates after TEVAR vary between 3.6%
Fig 1. Kaplan-Meier analysis (including 95% CI interval) regard-
ing reintervention-free survival of all patients (n  264).
Fig 2. Kaplan-Meier analysis showing no influence (log-rank test
P .1706) on survival for 58 patients with reintervention (1) vs no
reintervention (0) in 206 subjects.and 8.2% in the large multicenter trials performed to eval- iate the safety and efficiency of the three most commonly
sed endografts (TAG, Talent, Zenith TX2) and are thus
elow our reported rate.1-3 These trials included only pa-
ients with thoracic aortic aneurysms (TAG, Talent, TX2)
r PAU (TX2), with aortic dissections and CTD being an
xclusion criteria. Additionally, hybrid procedures were
nly included in regard to LSA revascularization. In our
eries, CEAD (13%), CTD (3.4%), and hybrid procedures
28%) significantly influenced reintervention and might,
herefore, explain a higher rate of reinterventions. Six out of
ine patients with CTD required reinterventions in this
eries, which supports a questionable midterm treatment
uccess of TEVAR in these patients. This findings correlate
ith Ehrlich et al that could show in the Talent thoracic
egistry Marfan syndrome to be the strongest independent
redictor for late conversion (HR, 9.7).12 Given excellent
esults for open surgery, the role of stent graft placement in
his subgroup might, therefore, be limited to bridging or
ostile operation fields (eg, after recurrent open surgery).
e perform TEVAR in these patients only under the
forementioned selection criteria.13-15
The second subgroup of patients requiring a high rate
f reinterventions (38%) in this series, were patients with
EAD. The reported reintervention rates for these patients
ary between 6% and 60% with endoleak formation and
ontinuing false lumen expansion, especially distal to the
overed aortic segment, being the most common cause of
econd procedure. Distal re-entries often prevent false lu-
en thrombosis and lead to retrograde perfusion, expan-
ion, and thus reintervention.16 Furthermore, segmental
rteries arising from the false lumen are usually not ex-
luded from retrograde blood flow in the false lumen.
dditional causes for reintervention in our series included
tent graft compression by the rigid dissection membrane
nd retrograde aortic dissection. In regard to these early
nd midterm complications, patient selection criteria (eg,
natomic considerations/timing of the procedure/amount
f re-entries) for a successful, durable TEVAR procedure
nd the ultimate role of TEVAR in patients with CEAD
ave yet to be defined.5,6,17-20 In our perspective, the
resent issue in patients with CEAD is to identify patients
ost prone to reintervention and to compare long-term
utcome in patients who underwent stent grafting. Despite
he fact of missing data on controlled efficacy, stent grafting
s an alternative option for high-risk surgical candidates
ith chronic aortic dissection. This is in line with the expert
onsensus document published in 2008.17
The most common cause of reintervention in this series
as the occurrence of an endoleak, which is in line with the
uropean Collaborators Registry (EUROSTAR) data, that
howed an increased risk for reintervention (relative risk,
.21) for patients with endoleaks.21 This is explicable as
ost endoleaks in the thoracic aorta are type I endoleaks
21 out of 27 in this series), which commonly demand
urther reintervention. In this series, 11/27 patients (41%)
equired proximal or distal debranching before stent graft
xtension to seal the endoleak. Reasons include short land-
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plex extended hybrid procedures. Type II endoleaks in the
thoracic aorta that required reintervention in this series
were via a covered LSA and a covered celiac trunk. We
generally only treat type II endoleaks with associated aneu-
rysm sac enlargement. Treatment of type II endoleaks of
the LSA included transbrachial placement of an Amplatzer
(AVP; AGAMedical, Plymouth, Minn) vascular plug prox-
imal to the origin of the left vertebral artery or open LSA
ligation/transposition. Persistent endoleaks via a covered
celiac trunk were sealed using coil embolization. A total of
7/68 reinterventions were associated with the LSA, which
includes three patients with a persistent endoleak type II
and four patients with persistent arm claudication/subcla-
vian steal syndrome. This is a result of our concept of
performing LSA revascularization prior to stent graft cov-
erage only in selected cases (eg, long covered aortic seg-
ment). We routinely evaluate the cerebral circulation (in-
cluding both vertebral arteries) prior to LSA coverage to
decide if carotid-subclavian transposition is needed at the
time of the TEVAR. Routinely, embolization of the origin
of the LSA before coverage to prevent type II endoleaks is
not performed.22 Aortobronchial or esophageal fistulas
(AEF) caused reintervention in four patients in this series.
The few available literature on this topic indicates that
TEVAR in patients with ABF can offer a definite treatment
solution, which could be proven in this series, where only
three out of nine patients required reintervention.23,24
Contrary to that, TEVAR is considered to be a bridging
method (as used in this series) for patients with AEF and
staged conversion is mostly recommended.25-27 Reported
conversion rates after TEVAR vary between 3.8% and 4.6%
with endoleaks, disease progression, retrograde aortic dis-
section, and aortoesophageal fistulas being the most com-
mon cause, which is in line with our series (conversion rate,
4.1%).12,28,29 There was a lower reintervention rate for
emergency cases in this series. This is possibly caused by the
higher mortality rate of patients requiring emergency TE-
VAR, leaving fewer patients at risk for reinterventions.30
The 1-, 3-, and 5-year reintervention-free survival rate
was 82%, 74%, and 70% in this series, which is in line with
Leurs et al who reported a 86% and 83% reintervention-free
survival rate after 1 and 2 years, respectively.21 Additionally,
their analysis of the EUROSTAR data showed a signifi-
cantly (P  .0001) reduced 2-year cumulative survival rate
(85% vs 58%) of patients requiring secondary interventions
after TEVAR. In our series, reintervention did not influ-
ence survival (P  .1706).
Lessons learned in the last decade of performing
TEVAR in our institution follows: (1) There is still no ideal
stent graft fitting all aortic pathologies, specifically in (2)
the aortic arch that is the “Achilles’ heel” of TEVAR.
Regarding these two issues, especially conformability and
radial force are key issues of future stent graft design to
reduce reintervention rates. (3) The indication to treat
acute uncomplicated type B dissections and chronic ex-
panding aortic dissections is still not solved. (4) Reinter-
ventions, especially in patients with connective tissue disor-ers are frequently necessary.13 (5) Accurate preoperative
maging with postprocessing using workstations added
ore useful information while planning, sizing, and select-
ng patients. Nevertheless, further dynamic imaging studies
nd research is needed to fully understand the geometry,
hysiology, and morphology of aortic pathologies and to
rovide future navigation tools. (6) Even knowing the risk
actors of spinal cord ischemia such as length of stented/
overed aorta, covering of LSA, and previous infrarenal
ortic replacement, clinical appearance of paraplegia re-
ains unpredictable and not fully understood. Surgical
eintervention options in these patients are unfortunately
imited or impossible.
Limitations. This patient cohort covers a large time
eriod, including the learning curve of the early worldwide
xperience with TEVAR. Although our reintervention rate
id not significantly change over the 13 years, this might
resumably be biased by the increasing complexity of
EVAR cases over the time, which is difficult to present in
n analysis like this. Due to the large spectrum of thoracic
ortic pathologies, patient heterogenity is an inherent lim-
tation of our approach. The present analysis represents
idterm results. At the 3-year follow-up, only 80/264
atients (30%) were “at risk for reintervention” (Fig 1).
easons include early andmidtermmortality in this cohort,
he referral pattern of our university center, and an increas-
ng number of patients treated during the last years of the
nalysis. It is thus possible that the actual number of rein-
erventions is underestimated and likely to increase during
urther long-term follow-up.
ONCLUSIONS
TEVAR is associated with a relevant reintervention
ate, predominately caused by endoleaks and progression of
he aortic pathology. Patients with chronic expanding aor-
ic dissections, hybrid aortic procedures, and connective
issue diseases are at an increased risk for reintervention and
hould therefore undergo close follow-up.
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